VC004 + rifampicin

VC004 + rifampicin refers to a clinical drug-drug interaction (DDI) study evaluating the impact of rifampicin, a potent cytochrome P450 (CYP3A4) inducer, on the pharmacokinetics of VC004. VC004 is a novel, small-molecule, next-generation tropomyosin receptor kinase (TRK) inhibitor, specifically acting as a TrkA antagonist. Developed by Jiangsu Vcare PharmaTech, VC004 is primarily being investigated for the treatment of locally advanced or metastatic NTRK fusion-positive solid tumors and brain metastases. The interaction study utilizes a single-center, open-label, fixed-sequence design in healthy adult subjects to determine how the induction of metabolic enzymes by rifampicin alters the systemic exposure and safety profile of VC004 capsules, which is essential for establishing clinical dosing guidelines.

Other names

VC004 and rifampicinVC-004 and rifampicinVC 004 and rifampicin